Want to see DE:FRE full AI Analyst Report?
Top Page
Fresenius SE & Co. KGaA
(XETRA:FRE)
Select Model
Select Model
Rating:63Neutral
Price Target:
€48.00
▲(9.59% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily supported by improved profitability and solid free cash flow with better leverage versus prior years. This is partly offset by weak technical momentum (below key moving averages with negative MACD) and a choppy multi-year revenue profile, while valuation and dividend yield provide a modest supportive backdrop.
Positive Factors
Free Cash Flow Strength
TTM free cash flow of €1.45B and consistently positive operating cash flow create durable internal funding for capex, R&D, and dividends. Strong cash conversion supports deleveraging and shields investments from short-term market volatility, improving long-term resilience.
Negative Factors
High Absolute Debt Load
Despite improved ratios, an absolute debt burden near €11.9B constrains financial flexibility. High nominal debt raises interest and refinancing exposure and limits capacity for large M&A or cyclical investments, making the company more sensitive to macro shocks or rising rates.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
TTM free cash flow of €1.45B and consistently positive operating cash flow create durable internal funding for capex, R&D, and dividends. Strong cash conversion supports deleveraging and shields investments from short-term market volatility, improving long-term resilience.
Read all positive factors
Fresenius SE & Co. KGaA (FRE) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€24.82B
Dividend Yield2.36%
Average Volume (3M)750.62K
Price to Earnings (P/E)16.7
Beta (1Y)0.83
Revenue Growth4.22%
EPS Growth248.36%
CountryDE
Employees177,783
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€54.94Price Target Upside25.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)3.54
Revenue Forecast (FY)€23.68B
Fresenius SE & Co. KGaA Business Overview & Revenue Model
Company Description
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across fou...
How the Company Makes Money
Fresenius makes money primarily by selling healthcare services and healthcare products through its operating businesses. A major revenue stream comes from providing dialysis treatment and related care to patients, where Fresenius earns fees (typic...
Fresenius SE & Co. KGaA Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
62
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.04B | 22.87B | 21.83B | 21.07B | 21.33B | 37.08B |
| Gross Profit | 5.82B | 5.69B | 5.38B | 4.97B | 5.20B | 9.81B |
| EBITDA | 3.60B | 3.75B | 3.13B | 2.69B | 3.09B | 6.93B |
| Net Income | 1.47B | 1.26B | 471.00M | -594.00M | 1.37B | 1.82B |
Balance Sheet | ||||||
| Total Assets | 42.37B | 41.40B | 43.55B | 45.28B | 76.42B | 71.96B |
| Cash, Cash Equivalents and Short-Term Investments | 2.06B | 1.58B | 2.05B | 2.56B | 2.35B | 2.75B |
| Total Debt | 11.90B | 11.93B | 13.58B | 15.83B | 27.76B | 27.16B |
| Total Liabilities | 21.90B | 21.63B | 23.26B | 25.63B | 44.20B | 42.67B |
| Stockholders Equity | 19.78B | 19.10B | 19.54B | 19.00B | 20.41B | 19.00B |
Cash Flow | ||||||
| Free Cash Flow | 1.45B | 1.20B | 1.52B | 3.32B | 2.28B | 3.03B |
| Operating Cash Flow | 2.92B | 2.69B | 2.45B | 4.46B | 4.20B | 5.08B |
| Investing Cash Flow | -868.00M | -942.00M | -510.00M | -3.19B | -2.61B | -2.82B |
| Financing Cash Flow | -2.40B | -2.42B | -2.18B | -1.38B | -1.60B | -1.45B |
Fresenius SE & Co. KGaA Technical Analysis
Positive
43.80
Price Trends
40.45
Positive
40.91
Positive
44.18
Positive
Market Momentum
1.12
Negative
66.42
Neutral
76.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FRE, the sentiment is Positive. The current price of 43.8 is above the 20-day moving average (MA) of 43.15, above the 50-day MA of 40.45, and below the 200-day MA of 44.18, indicating a bullish trend. The MACD of 1.12 indicates Negative momentum. The RSI at 66.42 is Neutral, neither overbought nor oversold. The STOCH value of 76.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FRE.
Fresenius SE & Co. KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €1.79B | 14.45 | 9.79% | 2.35% | 6.37% | 71.55% | |
66 Neutral | €195.70M | 6.89 | 11.90% | 0.94% | 2.94% | -14.28% | |
63 Neutral | €24.82B | 16.74 | 7.76% | 2.40% | 4.22% | 248.36% | |
60 Neutral | €1.45B | 43.42 | 4.19% | 1.82% | ― | ― | |
57 Neutral | €11.81B | 13.55 | 7.16% | 3.44% | -0.69% | 55.62% | |
57 Neutral | €863.51M | 21.50 | 3.04% | 1.55% | 6.06% | 0.93% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
DE:FRE
Fresenius SE & Co. KGaA
44.77
4.45
11.04%
DE:COP
CompuGroup Medical
27.50
4.40
19.03%
DE:DRW3
Draegerwerk AG & Co. KGaA
113.60
48.49
74.47%
DE:FME
Fresenius Medical Care AG & Co. KGaA
44.86
3.95
9.64%
DE:MED
MEDICLIN
4.10
1.11
37.22%
DE:RHK
RHON-KLINIKUM AG
12.90
1.09
9.25%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.